BioCryst Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $109,332 | $92,761 | $93,401 | $86,742 |
Gross Profit | 107,278 | 91,496 | 91,341 | 85,606 |
EBITDA | 9,081 | -10,151 | -42,247 | -7,737 |
EBIT | 8,761 | -10,457 | -42,670 | -8,157 |
Net Income | -12,674 | -35,379 | -61,731 | -36,149 |
Net Change In Cash | 109,332 | 92,761 | 93,401 | 86,742 |
Free Cash Flow | -1,925 | -53,919 | -9,472 | -20,884 |
Cash | 80,205 | 84,333 | 112,447 | 150,905 |
Basic Shares | 206,425 | 206,064 | 201,409 | 189,644 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $331,412 | $270,827 | $157,170 | $17,812 |
Gross Profit | 325,096 | 264,233 | 149,906 | 16,136 |
EBITDA | -102,054 | -143,308 | -177,658 | -165,337 |
EBIT | -103,709 | -144,745 | -178,435 | -166,085 |
Net Income | -226,539 | -247,117 | -184,062 | -196,567 |
Net Change In Cash | 331,412 | 270,827 | 157,170 | 17,812 |
Cost of Revenue | 233,386 | 158,625 | ||
Free Cash Flow | -97,309 | -163,201 | -144,542 | -137,730 |
Cash | 112,447 | 304,767 | 504,389 | 272,127 |
Basic Shares | 192,198 | 185,908 | 179,117 | 167,267 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.06 |
2024-03-31 | -$0.17 |
2023-12-31 | -$0.28 |
2023-09-30 | -$0.19 |
